Navigation Links
China-Biotics, Inc. Appoints New Chief Financial Officer
Date:3/6/2009

SHANGHAI, March 6 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced Lewis Fan will succeed Raymond Li as Chief Financial Officer, effective March 6, 2009. Mr. Li will continue to serve as Vice President of Finance to the Company.

Reporting to Mr. Jinan Song, Chairman and Chief Executive Officer, Mr. Fan will be responsible for all aspects of China-Biotics' finance functions, including accounting, financial planning, tax, treasury and audit. Prior to joining China-Biotics, Mr. Fan was Vice President and Senior Equity Analyst for Brean Murray, Carret & Co., where he covered the Chinese healthcare industry. He previously served as an equity analyst at UBS and as an emerging markets strategist at Deutsche Bank.

"I want to thank Raymond for his dedicated contributions as our Chief Financial Officer. He steered this company through its first public financing and has been chiefly responsible for our transition last year to the Nasdaq Global Market. We look forward to his continuing input and experience," said Mr. Song. "We are also excited to welcome Lewis as our new CFO. His combined technical knowledge in both finance and science will be an ideal fit as we move into the next phase of our life as a public company."

Prior to his Wall Street career, Mr. Fan served as a research scientist focusing on natural product drug discovery at Schering-Plough. He holds a Master of Business Administration degree in finance from New York University, a Master of Science degree in medicinal chemistry from the University of Michigan and a Bachelor of Arts degree with honors in biology and chemistry from Luther College.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

     CCG Investor Relations
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
2. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
3. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
4. China-Biotics, Inc. Retains KPMG for the Implementation of Sarbanes-Oxley Act Section 404
5. China-Biotics, Inc. Approved to List on the Nasdaq Global Market
6. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
7. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
8. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
9. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
10. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
11. China-Biotics, Inc. Files Application for Nasdaq Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... discovery and development of precision treatments for neurodegenerative diseases, today announced it has ... the ProMIS approach.” This is one of a series of commentaries from ProMIS’s ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... LabRoots ... and scientists from around the world, is pleased to announce the launch of a ... engineering and mathematics (STEM) fields. , This merit-based scholarship is open to all high ...
(Date:2/22/2017)... MOINES, Iowa , Feb. 22, 2017 Origin (Origin ... agricultural biotechnology trait and seed provider, and Arcadia ... -based company that develops and commercializes agricultural productivity traits and nutritional ... a key corn biotechnology product developed in China ... of global regulatory trials. ...
(Date:2/22/2017)... ROCHELLE, VIRGINIA (PRWEB) , ... February 22, 2017 ... ... announced today that Dr. Daniel Spyker, PhD, MD former Acting Deputy Director in ... in CDER’s Pilot Drug Evaluation Staff has joined the company as an Expert ...
Breaking Biology Technology:
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):